Language

English

Publication Date

4-3-2025

Journal

Molecular Cell

DOI

10.1016/j.molcel.2025.02.017

PMID

40101712

PMCID

PMC11972152

PubMedCentral® Posted Date

4-3-2026

PubMedCentral® Full Text Version

Author MSS

Abstract

ADAR1 regulates RNA-induced immune responses by converting adenosine to inosine in double-stranded RNA. Mutations in ADAR1 are associated with human autoimmune disease, and targeting ADAR1 has been proposed for cancer immunotherapy. However, the molecular mechanisms underlying ADAR1-mediated editing remain unclear. Here, we provide detailed biochemical and structural characterizations of human ADAR1. Our biochemical profiling reveals that ADAR1 editing is both sequence and RNA-duplex-length dependent but can well tolerate mismatches near the editing site. High-resolution ADAR1-RNA complex structures, combined with mutagenesis, elucidate RNA binding, substrate selection, dimerization, and the essential role of RNA-binding domain 3. The ADAR1 structures also help explain the potential defects of disease-associated mutations, where biochemical and RNA sequencing analysis further indicate some of the mutations preferentially impact the editing of RNAs with short duplexes. These findings unveil the molecular basis of ADAR1 editing and provide insights into its immune-regulatory functions and therapeutic potential.

Keywords

Adenosine Deaminase, Humans, RNA Editing, RNA-Binding Proteins, Mutation, RNA, Double-Stranded, Models, Molecular, HEK293 Cells, Binding Sites, Protein Binding, Inosine, Nucleic Acid Conformation, Protein Multimerization

Published Open-Access

yes

nihms-2060516-f0001.jpg (188 kB)
Graphical Abstract

Share

COinS
 
 

To view the content in your browser, please download Adobe Reader or, alternately,
you may Download the file to your hard drive.

NOTE: The latest versions of Adobe Reader do not support viewing PDF files within Firefox on Mac OS and if you are using a modern (Intel) Mac, there is no official plugin for viewing PDF files within the browser window.